Prostate cancer (PCa) is known as a challenging issue for the global men health due to its uncontrolled proliferation and high metastatic potential. Increasing evidence has supported plant extracts and plant-derived natural derivatives as a promising anti-tumor therapeutics as their less toxic side effects. Yuanhuacine is an active component isolated from Daphne genkwa and can effectively suppress tumorigenesis of several cancers. However, its role in PCa is still unclear. In this study, yuanhuacine dose-dependently inhibited PCa cell proliferation and induced cell apoptosis. Moreover, yuanhuacine treatment also restrained PCa cell invasion and migration. Mechanically, yuanhuacine decreased p53 protein ubiquitination, degradation and ultimately increased p53 levels, which was regulated by inhibiting phosphorylation and total protein levels of Mouse Double Minute 2 (MDM2). Moreover, elevation of MDM2 reversed the suppressive efficacy of yuanhuacine in PCa cell viability, invasion and migration. The network pharmacology and bioinformatics analysis confirmed that MDM2 might be a common target of Daphne genkwa and LINC00665. Furthermore, yuanhuacine reduced LINC00665 expression. Up-regulation of LINC00665 inversed yuanhuacine-mediated inhibition in MDM2 protein expression and suppressed p53 levels by enhancing its ubiquitination in yuanhuacine-treated cells. Importantly, the inhibitory effects of yuanhuacine on cell viability and metastatic potential were offset after LINC00665 elevation. Together, the current finding highlight that yuanhuacine may possess its tumor-suppressive efficacy by inhibiting LINC00665-mediated MDM2/p53 ubiquitination signaling. Therefore, this data indicate that yuanhuacine may be a promising candidate for the treatment of PCa.